A case study in the JAMA Internal Medicine found at least two cases in which patients developed severe liver damage immediately after taking rivaroxaban, the generic name for anticoagulant Xarelto. Researchers determined that the drug was responsible for drug-induced liver injury (DILI) in a 52 year-old man and 73-year old woman, adding to the lists of potential risks associated with Xarelto.
Xarelto is in a class of anticoagulants known as direct factor Xa inhibitors. Manufactured by Bayer and Johnson & Johnson, the drug was approved in 2011 to prevent blood clots, though Xarelto has since been tied to an increased risk of several severe side effects, including blood clots.
Nearly 2,000 adverse Xarelto events have been reported to the U.S. Food and Drug Administration since the drug was approved. Among those include patients who have suffered from pulmonary embolism, deep vein thrombosis, and internal hemorrhaging. More than 180 deaths have been associated with Xarelto.